ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

TEVA Teva Pharmaceutical Industries Ltd

16.98
0.03 (0.18%)
Pre Market
Last Updated: 12:03:11
Delayed by 15 minutes
Name Symbol Market Type
Teva Pharmaceutical Industries Ltd NYSE:TEVA NYSE Depository Receipt
  Price Change % Change Price High Price Low Price Open Price Traded Last Trade
  0.03 0.18% 16.98 6,093 12:03:11

AUSPEX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

30/03/2015 3:50pm

PR Newswire (US)


Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Teva Pharmaceutical Indu... Charts.

WILMINGTON, Del., March 30, 2015 /PRNewswire/ -- Rigrodsky & Long, P.A.:

  • Do you own shares of Auspex Pharmaceuticals, Inc. (NASDAQ GM: ASPX)?
  • Did you purchase any of your shares prior to March 30, 2015?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Auspex Pharmaceuticals, Inc. ("Auspex" or the "Company") (NASDAQ GM: ASPX) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Teva Pharmaceuticals Industries Ltd. ("Teva") (NYSE: TEVA), in a transaction valued at approximately $3.5 billion.

Click here to learn more: http://www.rigrodskylong.com/investigations/auspex-pharmaceuticals-inc-aspx.   

Under the terms of the agreement, public shareholders of Auspex would receive $101.00 in cash for each share of Auspex they own.

The investigation concerns whether Auspex's board of directors failed to adequately shop the Company and obtain the best possible value for Auspex's shareholders before entering into an agreement with Teva.  According to Yahoo! Finance, at least one analyst has issued a price target for Auspex stock at $105.00 per share.

If you own the common stock of Auspex and purchased your shares before March 30, 2015, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com, or at: http://www.rigrodskylong.com/investigations/auspex-pharmaceuticals-inc-aspx.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:
Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com 
http://www.rigrodskylong.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/auspex-pharmaceuticals-inc-shareholder-alert-rigrodsky--long-pa-announces-investigation-of-buyout-300057598.html

SOURCE Rigrodsky & Long, P.A.

Copyright 2015 PR Newswire

1 Year Teva Pharmaceutical Indu... Chart

1 Year Teva Pharmaceutical Indu... Chart

1 Month Teva Pharmaceutical Indu... Chart

1 Month Teva Pharmaceutical Indu... Chart

Your Recent History